X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (77) 77
index medicus (61) 61
female (52) 52
oncology (47) 47
middle aged (42) 42
male (38) 38
aged (35) 35
animals (28) 28
adult (26) 26
cancer (26) 26
metastasis (20) 20
treatment outcome (20) 20
chemotherapy (19) 19
mice (19) 19
expression (18) 18
prognosis (18) 18
survival (18) 18
aged, 80 and over (16) 16
hematology, oncology and palliative medicine (16) 16
therapy (16) 16
antineoplastic agents - therapeutic use (14) 14
angiogenesis (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
chemistry (13) 13
disease-free survival (13) 13
peptides (13) 13
breast neoplasms - drug therapy (12) 12
carcinoma, renal cell - drug therapy (12) 12
care and treatment (12) 12
kidney neoplasms - drug therapy (12) 12
microbiology (12) 12
neoplasm staging (12) 12
research (12) 12
urology (12) 12
analysis (11) 11
beer (11) 11
biochemistry (11) 11
compositions thereof (11) 11
culture media (11) 11
enzymology (11) 11
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (11) 11
investigating or analysing materials by determining theirchemical or physical properties (11) 11
measuring (11) 11
metallurgy (11) 11
microorganisms or enzymes (11) 11
mutation or genetic engineering (11) 11
organic chemistry (11) 11
physics (11) 11
propagating, preserving or maintaining microorganisms (11) 11
spirits (11) 11
testing (11) 11
vinegar (11) 11
wine (11) 11
cell biology (10) 10
immunohistochemistry (10) 10
efficacy (9) 9
immunology (9) 9
medical and health sciences (9) 9
medicin och hälsovetenskap (9) 9
sunitinib (9) 9
survival rate (9) 9
urology & nephrology (9) 9
3122 cancers (8) 8
biochemistry & molecular biology (8) 8
breast neoplasms - mortality (8) 8
breast neoplasms - pathology (8) 8
carcinoma, renal cell (8) 8
chemotherapy, adjuvant (8) 8
drug administration schedule (8) 8
molecular sequence data (8) 8
patients (8) 8
survival analysis (8) 8
taxoids - administration & dosage (8) 8
trastuzumab (8) 8
amino acid sequence (7) 7
apoptosis (7) 7
article (7) 7
breast cancer (7) 7
cancer therapies (7) 7
carcinoma, renal cell - mortality (7) 7
cell line (7) 7
cyclophosphamide - administration & dosage (7) 7
drug therapy (7) 7
flow cytometry (7) 7
gene expression regulation, neoplastic (7) 7
kidney neoplasms - mortality (7) 7
kidney neoplasms - pathology (7) 7
neoplasm metastasis (7) 7
proteins (7) 7
retrospective studies (7) 7
tumors (7) 7
vascular endothelial growth factor (7) 7
young adult (7) 7
antibodies, monoclonal, humanized (6) 6
antineoplastic agents - adverse effects (6) 6
base sequence (6) 6
cancer and oncology (6) 6
cancer och onkologi (6) 6
carcinoma (6) 6
cell adhesion (6) 6
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (196) 196
Finnish (7) 7
French (3) 3
German (2) 2
Italian (2) 2
Hungarian (1) 1
Norwegian (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 883 - 895
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 975 - 985
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1803 - 1813
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1700 - 1710
Summary Background Patients with advanced HER2-positive breast cancer frequently develop CNS metastases. The metastases that progress after brain radiotherapy... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CAPECITABINE | BIBW 2992 | EFFICACY | ONCOLOGY | MUTATIONS | ERBB FAMILY BLOCKER | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Vinblastine - therapeutic use | Brain Neoplasms - secondary | Breast Neoplasms - chemistry | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | Adult | Female | Receptor, ErbB-2 - antagonists & inhibitors | Brain Neoplasms - mortality | Antineoplastic Agents, Phytogenic - therapeutic use | Biomarkers, Tumor - antagonists & inhibitors | Republic of Korea | Antineoplastic Agents, Phytogenic - adverse effects | Brain Neoplasms - chemistry | Trastuzumab - therapeutic use | Biomarkers, Tumor - analysis | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Disease Progression | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Breast Neoplasms - mortality | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Care and treatment | Breast cancer | Product development | Metastasis | Antineoplastic agents
Journal Article
JAMA, ISSN 0098-7484, 03/2012, Volume 307, Issue 12, pp. 1265 - 1272
Journal Article
BJU International, ISSN 1464-4096, 01/2016, Volume 117, Issue 1, pp. 110 - 117
Journal Article